2016
Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial
Costa R, Abizaid A, Mehran R, Schofer J, Schuler G, Hauptmann K, Magalhães M, Parise H, Grube E, Investigators B. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovascular Interventions 2016, 9: 51-64. PMID: 26762911, DOI: 10.1016/j.jcin.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsFemaleGermanyHumansKaplan-Meier EstimateMaleMiddle AgedNeointimaPaclitaxelPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSingle-Blind MethodSirolimusStainless SteelSurface PropertiesTime FactorsTreatment OutcomeConceptsStent late lumen lossPaclitaxel-eluting stentsLate lumen lossDrug-coated stentsStent thrombosisBiolimus A9First-generation paclitaxel-eluting stentsDe novo coronary lesionsMajor adverse cardiac eventsPolymer-free biolimus A9Probable stent thrombosisAdverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationClinical event ratesLong-term outcomesLesion revascularizationAngiographic followCardiac eventsClinical outcomesCoronary lesionsLesions 4Lumen lossStandard doseStainless steel platform
2013
Impact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction
MINDRESCU C, BRENER S, GUERCHICOFF A, FAHY M, PARISE H, MEHRAN R, STONE G. Impact of Scheduled Angiographic Follow‐Up in Patients Treated With Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction. Journal Of Interventional Cardiology 2013, 26: 319-324. PMID: 23795656, DOI: 10.1111/joic.12038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionTarget vessel revascularizationPercutaneous coronary interventionPrimary percutaneous coronary interventionElevation myocardial infarctionMyocardial infarctionCoronary interventionStent thrombosisAcute Myocardial Infarction trialMyocardial Infarction trialOutcomes of patientsRate of revascularizationAngiographic Follow-upSAF groupRate of deathHarmonizing OutcomesVessel revascularizationCerebral eventsMI ratesFollow-upPatientsRevascularizationInfarctionComposite rateDeath
2012
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E, Stone G, Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 2012, 8: 599-606. PMID: 22995087, DOI: 10.4244/eijv8i5a92.Peer-Reviewed Original ResearchConceptsDAPT discontinuationCardiac deathSPIRIT IIST ratesDual antiplatelet therapy discontinuationDual antiplatelet therapy interruptionSPIRIT IIIAntiplatelet therapy discontinuationAntiplatelet therapy interruptionLarge pooled analysisRandomised clinical trialsTwo-year ratePatient-level databaseLog-rank testPES cohortTherapy discontinuationTherapy interruptionRandomised trialsStent thrombosisPaclitaxel-eluting stent deploymentPooled analysisClinical trialsDiscontinuationStent deploymentComposite rate
2011
Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus
Stone G, Kedhi E, Kereiakes D, Parise H, Fahy M, Serruys P, Smits P. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation 2011, 124: 893-900. PMID: 21824922, DOI: 10.1161/circulationaha.111.031070.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionEverolimus-eluting stentsDiabetes mellitusLesion revascularizationCoronary interventionStent thrombosisMyocardial infarctionStent typeIschemia-driven target lesion revascularizationEnd pointDifferential clinical responseXIENCE V EverolimusEfficacy end pointTarget lesion revascularizationTreatment of patientsCoronary stent systemSignificant differencesEverolimus-ElutingCoronary revascularizationEfficacy outcomesClinical responseDiabetic statusDiabetic patientsClinical outcomesHeparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarction